Remarkable response to Osimertinib plus Gumarontinib for EGFR mutation and concomitant MET exon 14 skipping in a patient with lung adenocarcinoma: A case report.

ABSTRACT: The evaluation of individuals with lung cancer for the presence of oncogenic mutations and the subsequent administration of personalized targeted therapies are of significance in clinical practice. Epidermal growth factor receptor (EGFR) mutation and mesenchymal-epithelial transition (MET) exon 14 skipping mutation were previously found to be mutually exclusive. The co-occurrence of these mutations in individuals diagnosed with adenocarcinomas signifies a distinctive and uncommon molecular subtype of non-small cell lung cancer. A 70-year-old man was admitted to Shandong Cancer Hospital and Institute (Jinan, Chian) with a 1-month history of chest pain. The CT scanning findings indicated the presence of a 5.8×5.6 cm mass in the left lower lobe, accompanied by enlarged mediastinal and hilar l

SUBMITTER: Jing X 

PROVIDER: S-EPMC12641465 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature